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ABSTRACT8
Epilepsy is a common neurologic disorder affecting approximately 1% of the population. The prevalence9
of active epilepsy in Kerman,Iran is 7.87/1000 individuals. The past decade has brought many advances10
to the treatment of epilepsy, including many new pharmacological agents. Lamotrigine is one of the new11
antiepileptic drugs. Lamotrigine has many side effects; the most important of which are allergic reactions.12
In this article, the author reports two cases of dopa- responsive dystonia (DRD) after few months13
administration of lamotrigine for epilepsy. The cases are two girls (4 and 5 years old) who had seizures14
and received lamotrigine 50 mg/day. They have been free of seizure after treatment but after some time15
the dystonic attacks developed. Lamotrigine administration discontinued, but dystonic attacks didn’t16
disappear. Levodopa /carbidopa was started. After a few days, the dystonic pastures disappeared. In17
conclusion, lamotrigine may introduce dystonia in susceptible patients. These dystonic attacks might18
beresponsive to levodopa.19
Keywords: ????20
Epilepsy is a common neurologic disorder affecting21
about 1% of the population [1]. The prevalence of22
active epilepsy in Kerman,Iran is 7.87/1000 individuals23
[2]. Pharmacotherapy with antiepileptic drugs remains24
the major treatment modality for epilepsy. This could25
occur as a result of decreased excitation concurrent with26
increased inhibition [3]. Management of epilepsy differs27
from the treatment of other chronic diseases in that a28
single breakthrough event has a major negative effect29
on quality of life. Complete control of seizures is30
necessary as a single seizure impacts negatively on31
patient quality of life and independence [4].32
The past decade has brought many advances to the33
treatment of epilepsy, including many new34
pharmacological agents. Lamotrigine is one of the new35
antiepileptic drugs; it’s been used more than two36
decades [5-7]. Lamotrigine is a broad-spectrum37
antiepileptic drug of the phenyltriazine class chemically38
unrelated to other anticonvulsants [8]. Lamotrigine has39
an average elimination half-life of 33 hours, although40
this can be influenced by concomitant therapy with41
other medications such as valproic acid. It’s42
predominantly metabolized in the liver by43
glucuronidation [9]. Lamotrigine has many side effects,44
most importantly allergic reactions. Gradual introducing45
lamotrigine is one of the keys to reduce the frequency46
and severity of allergic reactions [5]. Although the47
overall incidence of cutaneous reactions to lamotrigine48
is high, the incidence of serious eruptions such as49
erythema multiform, Stevens-Johnson syndrome, and50
toxic epidermal necrolysis is low [10,11]. The revision51
of La Roche and Helmers demonstrated that side-effects52
led to drug withdrawal in 10.2% of all patients under53
lamotrigine therapy. Rash was the main reason for54
treatment discontinuation. It has been postulated that55
side-effects may be lessened by slow introduction and56
titration [12,13].57
The present study reports two cases of dopa-58
responsive dystonia (DRD) after lamotrigine59
administration for a few months due to epilepsy. DRD60
is a broad term used to described forms of dystonia61
characterized by the onset dystonia in early childhood62
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with dramatic and sustained response to treatment with63
levodopa. This disorder was first described by Segawa64
[14]. The most common form of DRD is an autosomal-65
dominant condition (DYST5) caused by mutation of the66
gene for guanosine triphosphate cyclohydolase [15].67
CASE REPORTS68
Case 169
A 5 years old girl who used lamotrigine 50 mg per70
day due to tonic-clonic seizure and had her first attack71
of seizure two months before her first visit. After72
starting lamotrigine, the patient was free from seizure73
for one year. Dystonic pasture was developed in lower74
limb and after a time spread to lumbar spine, and then to75
the cervical area. Dystonic attacks worsened later in the76
day. Results of physical examinations, brain’s MRI77
scans and hematologic and serologic laboratory tests78
were normal. Dystonic pasture did not disappear after79
lamotrigine was discontinued. The dystonic attacks80
disappear after two days, when 50 mg per day81
levodopa/carbidopa wasstarted.82
Case 283
A 4 years old girl used lamotrigine 50 mg per day84
due to complex partial seizure. She had had her first85
attack of seizure a few months before her first visit.86
After receiving lamotrigine for two months, dystonic87
pasture developed in lower limb and then spread to88
lumbar spine. Dystonic pasture worsened later in the89
day. Physical examinations, brain’s MRI scans,90
hematologic and serologic laboratory tests were normal.91
Dystonic pasture did not disappear after lamotrigine92
discontinued. The dystonic attacks disappear after three93
days, when 50 mg per day levodopa/carbidopa was94
started.95
DISCUSSION96
DRDs are a group of disorders that show a good97
response to levodopa. The causes of these disorders are98
unknown, but the mutation of a gene is recognized in99
some studies. Onset of this disease usually happens in100
the first decade of life starting with foot dystonia, which101
progress to involve other body parts, but typically102
remains more sever in the lower extremities. The103
severity increases progressively over the first two104
decades of life, but plateaus with relatively few side105
effects and no long-term complication [16]. Untreated106
individuals developed diurnal fluctuations with marked107
improvement in the morning and worsening in the108
evening. DRDs are more frequent in female than in109
males, with a ratio varying from 1 to 4.3:1. Diagnosis of110
DRD can often be made on clinical grounds [17].111
There are reports about DRD induction by diazepam112
[18], bupropion [19], cetirizine [20], riluzole [21], and113
tetrabenazine [22]. The authors, however, didn’t find114
any reports about post-lamotrigine conditions.115
Lamotrigine is a new antiepileptic agent that is116
frequently used in epileptic patients with a good117
tolerability and efficacy. Lamotrigine has side effects,118
the most important of which is exfoliative dermatitis119
and rashes [23]. A study showed dizziness in 11%, and120
ataxia in 12% of cases, but if treatment begins with low121
doses, these events decreases [24]. Other side effects122
were also reported such as sudden death due to cardiac123
dysrhythmia in two cases [25], psychosis as one of the124
rare side effects of lamotrigine [13], oral ulcers [26],125
chorea [27], leucopenia and thrombocytopenia [28],126
anticonvulsant hypersensitivity syndrome [29],127
abnormal eye movements and hyper-sexuality [30]. This128
dystonic effect may be due to the lack of selectivity of129
lamotrigine to block glutamate release in susceptible130
individuals. In dystonic mutant hamsters when131
subsided, dystonia can be re-invoked when these132
animals receive sodium channel blockers such as133
lamotrigine [31- 34]. The patients under discussion are134
two girls (4 and 5 years old) who had seizure and135
received lamotrigine for a time and were free of seizure136
attacks. Dystonic attacks disappeared after receiving 50137
mg/per levodopa/ carbidopa. In conclusion, lamotrigine138
may introduce dystonia in susceptible patients. The139
dystonic attacks are responsive to levodopa.140
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